Skip to main content
Explore URMC
menu

CGIP19127 / A021602 / Aram Hezel

Research Question:
How well does cabozantinib S-malate work compared with placebo in treating patients with neuroendocrine tumors that have spread after previous treatment with everolimus?

Basic Study Information

Purpose:
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Cabozantinib is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

Location: University of Rochester Medical Center
Study Reference #: CGIP19127

Lead Researcher (Principal Investigator)

Lead Researcher:  Aram Hezel

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Return to Search